Drug Combination Details
| General Information of the Combination (ID: C57523) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | 2-deoxy-D-glucose Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | VOA1056 | CVCL_V536 | Adenocarcinoma | Homo sapiens | ||
| VOA1312 | CVCL_V538 | Adenocarcinoma | Homo sapiens | |||
| VOA5646 | CVCL_VQ39 | Adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
2-DG significantly inhibited glycolysis in all LGSOC lines and combination with metformin showed synergistic inhibitory effect. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecol Oncol. 2017 Aug;146(2):319-326. | |||
